Balance Sheet Details - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands |
Sep. 30, 2024 |
Dec. 31, 2023 |
|---|---|---|
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
| Other research and development | $ 25,674 | $ 30,759 |
| Other accrued expenses | 3,955 | 1,900 |
| Clinical studies | 1,124 | 2,156 |
| Acquired manufacturing rights | 0 | 25,000 |
| Total | $ 30,753 | $ 59,815 |
| X | ||||||||||
- Definition Acquired Manufacturing Rights, Current No definition available.
|
| X | ||||||||||
- Definition Clinical Studies No definition available.
|
| X | ||||||||||
- Definition Other research and development liabilities current. No definition available.
|
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|